Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions

被引:18
作者
Castellanos, Emily H. [1 ]
Wittmershaus, Brett K. [1 ]
Chandwani, Sheenu [1 ]
机构
[1] Flatiron Hlth Inc, 233 Spring St, New York, NY 10013 USA
关键词
SUPPORT;
D O I
10.1200/CCI.23.00046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEElectronic health record (EHR)-based real-world data (RWD) are integral to oncology research, and understanding fitness for use is critical for data users. Complexity of data sources and curation methods necessitate transparency into how quality is approached. We describe the application of data quality dimensions in curating EHR-derived oncology RWD.METHODSA targeted review was conducted to summarize data quality dimensions in frameworks published by the European Medicines Agency, The National Institute for Healthcare and Excellence, US Food and Drug Administration, Duke-Margolis Center for Health Policy, and Patient-Centered Outcomes Research Institute. We then characterized quality processes applied to curation of Flatiron Health RWD, which originate from EHRs of a nationwide network of academic and community cancer clinics, across the summarized quality dimensions.RESULTSThe primary quality dimensions across frameworks were relevance (including subdimensions of availability, sufficiency, and representativeness) and reliability (including subdimensions of accuracy, completeness, provenance, and timeliness). Flatiron Health RWD quality processes were aligned to each dimension. Relevancy to broad or specific use cases is optimized through data set size and variable breadth and depth. Accuracy is addressed using validation approaches, such as comparison with external or internal reference standards or indirect benchmarking, and verification checks for conformance, consistency, and plausibility, selected on the basis of feasibility and criticality of the variable to the intended use case. Completeness is assessed against expected source documentation; provenance by recording data transformation, management procedures, and auditable metadata; and timeliness by setting refresh frequency to minimize data lags.CONCLUSIONDevelopment of high-quality, scaled, EHR-based RWD requires integration of systematic processes across the data lifecycle. Approaches to quality are optimized through knowledge of data sources, curation processes, and use case needs. By addressing quality dimensions from published frameworks, Flatiron Health RWD enable transparency in determining fitness for real-world evidence generation.
引用
收藏
页数:13
相关论文
共 45 条
[1]   Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study [J].
Agarwala, Vineeta ;
Khozin, Sean ;
Singal, Gaurav ;
O'Connell, Claire ;
Kuk, Deborah ;
Li, Gerald ;
Gossai, Anala ;
Miller, Vincent ;
Abernethy, Amy P. .
HEALTH AFFAIRS, 2018, 37 (05) :765-772
[2]  
[Anonymous], NICE real-world evidence framework: Assessing data suitability
[3]  
[Anonymous], 2023, The National Cancer Plan
[4]  
[Anonymous], Blueprint for trustworthy AI implementation guidance and assurance for healthcare
[5]  
[Anonymous], CodeX HL7 FHIR accelerator
[6]  
[Anonymous], ISO 31000 Risk Management
[7]  
Ascha M, 2022, PHARMACOEPIDEM DR S, V31, P546
[8]   The Evolving Uses of "Real-World" Data [J].
Basch, Ethan ;
Schrag, Deborah .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (14) :1359-1360
[9]  
Birnbaum B, 2020, Arxiv, DOI arXiv:2001.09765
[10]   Use of Real-world Data for New Drug Applications and Line Extensions [J].
Bolislis, Winona R. ;
Fay, Myriam ;
Kuhler, Thomas C. .
CLINICAL THERAPEUTICS, 2020, 42 (05) :926-938